CoChat

Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double‐blind controlled trial

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Fatigue is a common symptom in primary biliary cirrhosis (PBC). In animal models of cholestasis, abnormalities in serotonin neurotransmission are observed with fatigue. The role of selective serotonin reuptake inhibitors in fatigue-related PBC, however, is unknown. A double-blind, placebo-controlled study design was conducted to determine the safety and efficacy of fluoxetine for the treatment of fatigue in PBC. Patients were randomized to fluoxetine, 20 mg daily, or matched placebo for 8 weeks' duration. Fatigue was assessed by the Fisk Fatigue Impact Scale (FFIS). The primary study endpoint was a > or =50% reduction in overall FFIS score at the end of treatment. Health-related quality of life (HRQL) was assessed as a secondary endpoint. Among 220 consecutively screened patients, only 18 (9%) eligible individuals were randomized to fluoxetine (n=10) or placebo (n=8) for 8 weeks. Baseline variables including median FFIS scores (52 vs 42; P=0.21) were similar between treatment arms (P > 0.05). After 8 weeks of therapy, no statistically significant change in median FFIS score was observed in the fluoxetine group. Median FFIS score in the placebo group was reduced (42 to 28), but not statistically significant. No difference in HRQL was observed between treatment arms after 8 weeks. Fourteen (78%) patients completed therapy, while four (22%) individuals withdrew from the trial. Three of the four patients had drug-related adverse events with fluoxetine. In this study, fluoxetine did not improve fatigue in PBC and was associated with adverse events.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10620-006-9397-5

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 56

Metadata

Authors
Talwalkar, J. A., Donlinger, J. J., Gossard, A. A., Keach, J. C., Jorgensen, R. A., Petz, J. C., & Lindor, K. D.
Affiliations
Mayo Clinic (US)
Corresponding author
Talwalkar, Jayant A.
Venue
Digestive Diseases and Sciences
Published
2006-10-20
Volume
51
Issue
11
Pages
1985-1991
ISSN
  • 0163-2116 (ISSN-L)
  • 1573-2568
OpenAlex
W2024885291
Cited by
54
References
35
Citations by year
2026: 2 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 4 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 1 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 2
FWCI
2.72
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Digestive Diseases and Sciences (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords
fluoxetine, primary biliary cirrhosis, fatigue, selective serotonin reuptake inhibitors, serotonergic neurotransmission, cholestasis, health-related quality of life, drug adverse events
MeSH terms
Adolescent, Adult, Aged, Double-Blind Method, Fatigue, Fluoxetine, Humans, Liver Cirrhosis, Biliary, Middle Aged, Prospective Studies, Quality of Life, Treatment Outcome, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double‐blind controlled trial. https://app.cochat.ai/papers/10.1007/s10620-006-9397-5
The paper
Talwalkar, J. A., Donlinger, J. J., Gossard, A. A., Keach, J. C., Jorgensen, R. A., Petz, J. C., & Lindor, K. D. (2006). Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double‐blind controlled trial. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-006-9397-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.